As expected, the European Commission approves Bristol Myers Squibb’s (NYSE:BMY) Reblozyl (luspatercept) for the treatment of adults with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based therapy and adults with transfusion-dependent anemia associated with beta thalassemia.
About two months ago, the advisory group CHMP adopted a positive opinion backing approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.